NASDAQ: FDMT4d Molecular Therapeutics Inc Stock
$11.09+0.10 (+0.91%)
Updated Jul 20, 2026
FDMT Price
$11.09
Fair Value Price
N/A
Market Cap
$579.74M
52 Week Low
$4.21
52 Week High
$14.00
P/E
-4.32x
P/B
1.28x
P/S
7.18x
PEG
N/A
Dividend Yield
N/A
Revenue
$88.24M
Earnings
-$160.90M
Gross Margin
100%
Operating Margin
-182.34%
Profit Margin
-182.3%
Debt to Equity
0.14
Operating Cash Flow
-$129M
Beta
1.32
Next Earnings
Aug 10, 2026
Ex-Dividend
N/A
Next Dividend
N/A
FDMT Overview
4D Molecular Therapeutics, Inc. is a clinical-stage gene therapy that uses adeno-associated virus vectors to develop product candidates in three therapeutic areas: ophthalmology, cardiology, and pulmonology. 4D Molecular Therapeutics has research and collaboration arrangements with uniQure, CRF, Roche, and CFF. The company was founded in 2013 and is headquartered in Emeryville, CA.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine FDMT's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -6.47% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
FDMT
Ranked#291 of 464
Ranked#291 of 464
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $243.47 | A | |
| $11.15 | A | |
| $8.60 | A |
Be the first to know about important FDMT news, forecast changes, insider trades & much more!
FDMT News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how FDMT scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
FDMT is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
FDMT is good value based on its book value relative to its share price (1.28x), compared to the US Biotechnology industry average (5.33x)
P/B vs Industry Valuation
FDMT is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more FDMT due diligence checks available for Premium users.
Valuation
FDMT price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-4.32x
Industry
21.5x
Market
11.71x
FDMT price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.28x
Industry
5.33x
FDMT is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
FDMT's financial health
Profit margin
Revenue
$3.0M
Net Income
-$68.8M
Profit Margin
-2,256.6%
FDMT's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
FDMT's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$512.9M
Liabilities
$61.1M
Debt to equity
0.14
FDMT's short-term assets ($405.36M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
FDMT's short-term assets ($405.36M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
FDMT's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
FDMT's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$68.1M
Investing
$68.9M
Financing
$11.5M
FDMT's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
FDMT vs Biotech Stocks
4d Molecular Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.